In this slide show we highlight some of the top news on lung cancer in 2017, including FDA approvals, a new standard of care for ALK-positive lung cancer, increased risk with vitamin B supplements, and more.
Lung Cancer Year in Review 2017
While the incidence of irAEs is relatively low, the absolute number of patients receiving immune checkpoint inhibitors is steadily increasing. Thus, it is likely that, with time, larger numbers of patients will develop irAEs, including pneumonitis.
Stereotactic Body Radiation Therapy as an Alternative to Surgery in Early-Stage Non–Small-Cell Lung Cancer
Three randomized trials of SBRT vs surgical resection closed due to poor accrual, but an analysis of patients treated in these trials suggested that SBRT might even be superior to surgery. New trials are underway to further assess the question of whether SBRT can be the definitive treatment for early-stage NSCLC instead of surgery.
In this interview we discuss the role of checkpoint inhibitors in advanced lung cancer and treatment strategies when patients progress.
Understanding the Links Between Lung Cancer, COPD, and Emphysema: A Key to More Effective Treatment and Screening
A better delineation of the relationships between lung cancer, COPD, and emphysema may lead to significant improvements in the effectiveness of lung cancer screening programs, and to reductions in the morbidity and mortality associated with these deadly diseases.